Indaptus Therapeutics
Open
$3.60
Prev. Close
$3.60
High
$3.79
Low
$3.60
Market Snapshot
$8.34M
-0.4
-45.50
5
Indaptus Therapeutics, Inc. is a clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 5 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Indaptus Therapeutics, Inc. is a clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 5 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Recently from Cashu
It seems that you haven't provided any content or article to summarize. Please share the content, and I'll create a summary title for you.
Please provide the relevant content or article that you would like me to summarize, and I will create the summary as you requested.
Indaptus Therapeutics Pioneers Innovative Immunotherapy Advancements in Cancer Treatment
Indaptus Therapeutics Advances Innovative Cancer Treatment Strategy Indaptus Therapeutics is making significant strides in its mission to revolutionize cancer treatment through its proprietary platfor…
Indaptus Therapeutics Faces Market Skepticism Amid 26.44% Rise in Short Interest
Indaptus Therapeutics Faces Growing Market Skepticism Amid Rising Short Interest Indaptus Therapeutics Inc. is currently experiencing a significant increase in short interest, which has risen by 26.44…
Indaptus Therapeutics: Strategic Innovations Drive Stock Surge Amid Biotech Challenges
Indaptus Therapeutics: Strategic Advancements in Therapeutic Development Indaptus Therapeutics Inc. is at a pivotal moment as it navigates the complexities of the biotechnology sector. The company is…